<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; RDY</title>
	<atom:link href="http://www.stockbloghub.com/tag/rdy/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) US Court Rejects AstraZeneca&#8217;s Case</title>
		<link>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196</link>
		<comments>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196#comments</comments>
		<pubDate>Thu, 19 Apr 2012 20:24:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97196</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA). AstraZeneca had taken legal action against the FDA, challenging the agency’s decision to reject AstraZeneca’s Citizen Petitions. The Citizen Petitions were filed by the company for Seroquel (quetiapine fumarate) and Seroquel XR. The Citizen Petitions were filed to bar the FDA from approving any generic versions of the drug that do not include warnings related to hyperglycemia and suicidality in its label. With this move, AstraZeneca was looking to delay the launch of generic versions of Seroquel considering the company has marketing exclusivity for the data associated with the hyperglycemia warning till December 2, 2012. Meanwhile, the UK High Court has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor</title>
		<link>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086</link>
		<comments>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086#comments</comments>
		<pubDate>Tue, 06 Dec 2011 17:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88086</guid>
		<description><![CDATA[November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator and its loss of exclusivity could very well represent the biggest generic opportunity in recent times. Lipitor sales came in at $10.7 billion in 2010 with sales for the first nine months of 2011 coming in at $7.6 billion. Pfizer Goes Aggressive Typically, whenever a branded drug loses exclusivity, it witnesses a rapid erosion in sales with the entry of generic versions. However, Pfizer is trying to turn the tide in its favor by adopting several steps to minimize the impact of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISR) IsoRay&#8217;s GliaSite Gets Final Nod</title>
		<link>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635</link>
		<comments>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:45:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[IsoRay Inc]]></category>
		<category><![CDATA[ISR]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87635</guid>
		<description><![CDATA[IsoRay Inc (ISR), which makes the Cesium-131 internal radiation therapy (brachytherapy) isotope, has crossed the last regulatory hurdle for its GliaSite radiation therapy system, a balloon catheter used in treating brain cancer. The product has been cleared by the Washington State Department of Health, representing the final step required to commence its commercialization in the U.S. GliaSite was approved by the U.S. Food and Drug Administration (“FDA”) in September 2011. IsoRay had acquired the exclusive global distribution rights to GliaSite from Hologic Inc (HOLX) in June 2010. The company, in June 2011, secured the exclusive global licensing rights to Iotrex, a key component in the GliaSite system, from Dr. Reddy’s Laboratories (RDY). Brain cancer is among the fastest growing cancers with more than 575 people being diagnosed with this condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019</link>
		<comments>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019#comments</comments>
		<pubDate>Fri, 28 Oct 2011 15:52:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86019</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported second quarter fiscal 2012 earnings per American Depositary Share (ADS) of 40 cents, significantly above the year-ago earnings of 30 cents per ADS. Higher revenues helped boost earnings. Quarter at a Glance The company reported revenues of $462 million during the fiscal year, reflecting a year-over-year increase of 22%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). While, revenues at the Global Generics segment increased 18% to $329 million, PSAI revenues shot up 28% to $121 million during the quarter. While generics revenues increased 45% in North America, 23% in Russia and other CIS (Commonwealth of Independent States) markets, and 9% in India, they deteriorated 10% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Earns FDA Approval for Generic</title>
		<link>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064</link>
		<comments>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:48:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79064</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline plc (GSK) for preventing deep vein thrombosis (DVT) in adults who are undergoing hip fracture, hip replacement, or knee replacement surgery. Dr. Reddy’s received final approval from the FDA for the 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of fondaparinux sodium injection. Dr. Reddy’s will be manufacturing the generic version under license using a patented process that is developed by Australia based Alchemia Limited. The current approval comes close on the heels of the US launch of the generic version of Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin</title>
		<link>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444</link>
		<comments>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77444</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson &#38; Johnson’s (JNJ) antibiotic drug, Levaquin, in the US. Data from IMS Health reveal that the branded product recorded sales of $1.1 billion in the trailing twelve months ending March 2011. Only recently Dr. Reddy’s announced the launch of three other generic products in the US. The company launched the generic versions of Pfizer Inc.’s (PFE) anti-depressant, Effexor XR, Eisai Co. Ltd.’s Alzheimer’s treatment, Aricept, and Novartis AG’s (NVS) breast cancer treatment, Femara. We believe that the launches of all these generic drugs will bring in additional revenues for Dr. Reddy’s Global Generics segment, which recorded sales of $1.2 billion in fiscal 2011 (ending March 2011), reflecting a sharp year-over-year increase of 10%. Interestingly we note ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISR) IsoRay Begins Prostate Cancer Trial</title>
		<link>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129</link>
		<comments>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129#comments</comments>
		<pubDate>Wed, 22 Jun 2011 21:14:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[IsoRay Inc]]></category>
		<category><![CDATA[ISR]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TGX]]></category>
		<category><![CDATA[Theragenics Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77129</guid>
		<description><![CDATA[Medical isotope maker IsoRay Inc (ISR) has initiated a new combination therapy study using its Cesium-131 (an isotope) internal radiation therapy (“brachytherapy”) and external beam radiation. The study has been designed to evaluate the effectiveness of combining Cesium-131 brachytherapy with intensity modulated radiation therapy (“IMRT”) in treating intermediate and high risk prostate cancer. Prostate cancer is the second most prevalent cancer (after skin cancer) among American men and the second-leading cause (after lung cancer) of cancer-related death. High level of PSA (a protein produced in the prostate) generally indicate the presence of this disease. More than 30,000 people succumb to prostate cancer annually in the U.S. Based on the available study results, the dual therapy (brachytherapy and external beam radiation) has shown to offer major benefits to prostate cancer patients. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/isr-isoray-begins-prostate-cancer-trial/77129/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter</title>
		<link>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483</link>
		<comments>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:27:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76483</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca, Mexico, which produces Intermediates and Active Pharmaceutical Ingredients. In the four-item warning letter, the FDA has asked for additional data and corrective actions for certain listed items. In order to respond to the warning letter within the stipulated timeframe, Dr. Reddy’s plans to work closely with the regulatory body and resolve the matters contained in the letter. Earlier, in November last year, after inspecting Dr. Reddy’s Mexico facility, the FDA had issued Form FDA 483, with observations. The company responded to the observations by implementing a number of corrective actions. Earlier this week, Dr. Reddy’s announced the launch of three generic products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172</link>
		<comments>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172#comments</comments>
		<pubDate>Fri, 03 Jun 2011 14:11:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74172</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses helped boost earnings. Year at a Glance The company reported revenues of $1.7 billion during the fiscal year, reflecting a year-over-year increase of 6%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). Revenues at the Global Generics segment increased 10% to $1.2 billion. However, PSAI revenues declined 4% to $441 million during the year. While generics revenues increased 18% in North America, 19% in Russia and other CIS (Commonwealth of Independent States) markets, and 15% in India, they deteriorated 13% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058</link>
		<comments>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058#comments</comments>
		<pubDate>Fri, 27 May 2011 13:41:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75058</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million. The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US. The Medicines Company received a major boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck in Joint Venture with Sun Pharma</title>
		<link>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:20:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71361</guid>
		<description><![CDATA[Merck &#38; Co., Inc. (MRK) recently announced that it is setting up a joint venture (JV) with Indian multinational pharma company, Sun Pharmaceutical Industries Ltd. The joint venture is for the development, manufacture and commercialization of new combinations and formulations of innovative, branded generics in emerging markets. While financial details of the transaction were not disclosed, the companies said that Sun Pharma’s proprietary platform technologies would be used for the development of products. Meanwhile, Merck will contribute its expertise in clinical development and registration activities. Moreover, Merck will also be bringing its commercial expertise and global reach to the joint venture. Deal in-line with Merck’s Growing Focus on Emerging Markets The joint venture is in-line with Merck’s growing focus on emerging markets. The company has been working on growing its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr Reddy’s Laboratories Reports Respectable Second Quarter 2011 Earnings</title>
		<link>http://www.stockbloghub.com/2010/10/25/rdy-dr-reddy%e2%80%99s-laboratories-reports-respectable-second-quarter-2011-earnings/56399</link>
		<comments>http://www.stockbloghub.com/2010/10/25/rdy-dr-reddy%e2%80%99s-laboratories-reports-respectable-second-quarter-2011-earnings/56399#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:49:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56399</guid>
		<description><![CDATA[Dr Reddy’s Laboratories (RDY) reported second quarter fiscal 2011 earnings per American Depository Share (ADS) of 40 cents compared with earnings of 30 cents in the year-ago period. Higher gross margin led to an increase in earnings. Revenues The company reported quarterly revenues of $420 million, up 2%. Dr Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). Global Generics segment revenues went up 8% (on an INR basis), while PSAI revenues declined 14% (on an INR basis) during the second quarter. Generics revenues (on an INR basis) increased 3% in North America, 17% in Russia &#38; other CIS markets and 25% in India, while it declined 17% in Europe. The European market recorded the highest decline among all the regions with Germany ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/rdy-dr-reddy%e2%80%99s-laboratories-reports-respectable-second-quarter-2011-earnings/56399/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Biocon Enter Gloabal Diabetes Deal</title>
		<link>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694</link>
		<comments>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694#comments</comments>
		<pubDate>Wed, 20 Oct 2010 05:28:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55694</guid>
		<description><![CDATA[Pfizer (PFE) recently entered into a global agreement with Indian biotech company Biocon, for certain diabetes biosimilars. The deal relates to the global commercialization of biosimilar versions of insulin and insulin analog products like recombinant human insulin, glargine, aspart and lispro. Terms of the Deal Per the terms of the deal, Pfizer will commercialize these products across the world excluding certain territories. The company will share commercialization rights with Biocon for all these products in Germany, India and Malaysia. In case of several developing markets, Pfizer will share commercialization rights with existing licensees. Biocon will be responsible for developing, manufacturing, supplying and gaining regulatory approval for these products. We note that Biocon’s version of recombinant human insulin is already approved in 27 developing markets. Meanwhile, the biosimilar version of Sanofi-Aventis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Announces Aquisition of Indian Company Piramal Healthcare</title>
		<link>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974</link>
		<comments>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974#comments</comments>
		<pubDate>Fri, 10 Sep 2010 16:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50974</guid>
		<description><![CDATA[Abbott Labs (ABT) recently completed its acquisition of Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.8 billion. In addition to an upfront payment of $2.2 billion, Abbott Labs will pay $400 million annually over the next 4 years. Position Strengthened in Indian Pharma Market The acquisition of Piramal’s Healthcare Solutions business should catapult Abbott Labs to the top position in the Indian pharmaceutical market, which is one of the world&#8217;s fastest-growing. The Healthcare Solutions business, which is now a part of Abbott Labs’ Established Products Division, grew 23% in fiscal 2010 and has a presence in several therapeutic areas including antibiotics, respiratory, cardiovascular, pain and neuroscience. The Established Products Division focuses on branded generics especially in emerging markets. Abbott Labs estimates that the Indian pharma market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Settles Patent Fight</title>
		<link>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919</link>
		<comments>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919#comments</comments>
		<pubDate>Mon, 26 Jul 2010 21:35:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44919</guid>
		<description><![CDATA[Forest Laboratories Inc. (FRX) and partner Merz GmbH &#38; Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their generic versions of Alzheimer&#8217;s drug Namenda (memantine). As per the settlement agreement, the generic version of the drug will enter the market on January 11, 2015, three months before the patent expires in April 2010. This settlement agreement is subject to review by the US government. While Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI), Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Mylan Inc. (MYL), Teva Pharmaceutical Industries Ltd. (TEVA) and a few other companies, the dispute is still ongoing with certain other generic manufacturers. We believe Forest Labs and Merz will seek to settle with these companies as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories to Buy Piramal Healthcare Unit</title>
		<link>http://www.stockbloghub.com/2010/05/24/abt-abbott-laboratories-to-buy-piramal-healthcare-unit/38125</link>
		<comments>http://www.stockbloghub.com/2010/05/24/abt-abbott-laboratories-to-buy-piramal-healthcare-unit/38125#comments</comments>
		<pubDate>Mon, 24 May 2010 21:04:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38125</guid>
		<description><![CDATA[Abbott Laboratories (ABT) is all set to acquire Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.72 billion. Per the terms of the definitive agreement with Piramal, Abbott will make an upfront payment of $2.12 billion, and annual payments of $400 million for the next 4 years. This acquisition should catapult Abbott to the top position in the Indian pharmaceutical market which is one of the world&#8217;s fastest-growing pharmaceutical markets. The Healthcare Solutions business, which will become a part of Abbott’s Established Products Division, grew 23% in fiscal 2010 and has a presence in several therapeutic areas including antibiotics, respiratory, cardiovascular, pain and neuroscience. According to Abbott, the Indian pharma market is expected to generate $8 billion in sales this year – this amount is expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/abt-abbott-laboratories-to-buy-piramal-healthcare-unit/38125/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214</link>
		<comments>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214#comments</comments>
		<pubDate>Thu, 28 Jan 2010 01:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26214</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts covering the stock raising fourth quarter estimates in the last 30 days. In terms of earnings surprises, Watson had a modest positive surprise in the third quarter and a 7% positive surprise in the second quarter of 2009, with the four-quarter average of 8%. (This means, on average, Watson has come ahead of the Zacks Consensus by 8% over the last four quarters.) If quarterly results come in-line with expectations, fourth quarter 2009 EPS would be 35.8% above the year-ago level. However, chances are high that there could be a positive surprise of 1.4% for the upcoming ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr Reddy’s Laboratories Reports Earnings and Slashes Guidance</title>
		<link>http://www.stockbloghub.com/2010/01/21/rdy-dr-reddy%e2%80%99s-laboratories-reports-earnings-and-slashes-guidance/25614</link>
		<comments>http://www.stockbloghub.com/2010/01/21/rdy-dr-reddy%e2%80%99s-laboratories-reports-earnings-and-slashes-guidance/25614#comments</comments>
		<pubDate>Thu, 21 Jan 2010 19:30:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25614</guid>
		<description><![CDATA[Recently, Dr Reddy’s Laboratories (RDY) announced third quarter loss per ADS of 70 cents after a write-down of $174 million associated with its betapharm business in Germany and other intangibles. Excluding these, the company reported adjusted earnings per share of 29 cents, lower than the Zacks Consensus Estimate of 37 cents. Dr Reddy’s reported revenues of $373 million, a 6% decline from $397 million reported in the year-ago period. Revenues grew 17% excluding the contribution from sumatriptan in the previous year. Earlier, in November 2008, Dr Reddy’s launched the authorized generic version of GlaxoSmithKline’s (GSK) Imitrex (sumatriptan succinate) tablets in the US . Dr Reddy’s being the first company to launch the authorized generic version of the drug, enjoyed exclusivity till August 2009 after which other players entered the market. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/21/rdy-dr-reddy%e2%80%99s-laboratories-reports-earnings-and-slashes-guidance/25614/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Set to Top Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019</link>
		<comments>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:21:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25019</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range of $2.50 &#8211; $2.58 per share. Watson also announced that it expects revenues to increase 9% year over year to $2.7 billion in 2009. The company’s shares reacted positively to the news, with the stock gaining roughly 3.5% since the announcement. The statement, which was made at the 28th Annual J.P. Morgan (JPM) Healthcare Conference, is based on a preliminary review of the company’s performance in the fourth quarter and year-ended December 31, 2009. Watson attributed the robust performance to strong contributions from its new generic and brand products, and significant growth in distribution revenues in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Exercises Drug Option</title>
		<link>http://www.stockbloghub.com/2010/01/12/gsk-glaxosmithkline-exercises-drug-option/24811</link>
		<comments>http://www.stockbloghub.com/2010/01/12/gsk-glaxosmithkline-exercises-drug-option/24811#comments</comments>
		<pubDate>Wed, 13 Jan 2010 06:04:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24811</guid>
		<description><![CDATA[Recently, GlaxoSmithKline (GSK) exercised its option to obtain exclusive license regarding further development and commercialization of ChemoCentryx&#8217;s Traficet-EN, a specific CCR9 antagonist. The drug candidate is meant for the treatment of inflammatory bowel diseases Incorporatedluding Crohn&#8217;s disease. Under the terms of the agreement, ChemoCentryx will receive an option exercise fee of $35 million as well as milestone payments. In addition, on successful commercialization, ChemoCentryx will receive royalties on sales of the drug. Following the option exercise, Glaxo will be responsible for further development of Traficet-EN. We believe Glaxo is strengthening its pipeline to meet the patent challenges in the forthcoming period. Several products like Valtrex, Coreg IR, and Requip are all facing declining sales due to intense generic competition. The entry of generic versions of Merck’s (MRK) Cozaar is likely ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/gsk-glaxosmithkline-exercises-drug-option/24811/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593</link>
		<comments>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593#comments</comments>
		<pubDate>Sun, 10 Jan 2010 23:33:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24593</guid>
		<description><![CDATA[We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral&#8221; recommendation and a target price of $42. The company enjoys a strong position in the generics market. We believe the company’s strategy of developing generics that are difficult to formulate or manufacture will help strengthen its position in the market. Going forward Incorporatedreasing awareness about generics, initiatives taken by various government and private agencies encouraging the use of low-cost generics, an aging population and a corresponding increase in healthcare costs, as well as the large number of branded products losing patent protection over the coming years, should lead to continued expansion of the generics market. We also believe that Watson’s recent acquisition of Arrow will help the company expand its footprint in ex-U.S. territories, and will also boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer Joins With Strides Arcolab For Off-Patent Generics in the U.S.</title>
		<link>http://www.stockbloghub.com/2010/01/08/pfe-pfizer-joins-with-strides-arcolab-for-off-patent-generics-in-the-u-s/24496</link>
		<comments>http://www.stockbloghub.com/2010/01/08/pfe-pfizer-joins-with-strides-arcolab-for-off-patent-generics-in-the-u-s/24496#comments</comments>
		<pubDate>Fri, 08 Jan 2010 20:16:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24496</guid>
		<description><![CDATA[Pfizer, Inc. (PFE) recently joined hands with Indian company Strides Arcolab for the commercialization of off-patent sterile injectable and oral products in the United States. As per the agreement, these products will be commercialized through the company&#8217;s Established Products Business Unit. Strides and its joint ventures with Aspen, Onco Laboratories Limited and Onco Therapies Limited, will supply the finished products to Pfizer. About 40 off-patent products, mostly oncology therapeutics, will be delivered by Strides under this agreement. The companies will start launching products under this agreement from this year. Pfizer is already an established player in the injectable market, offering medicines from antibiotics to cancer therapies and the Strides deal will help boost its product offering. Pfizer markets injectables like Bacitracin, Camptosar, Zithromax IV, and Diflucan among others. We believe ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/pfe-pfizer-joins-with-strides-arcolab-for-off-patent-generics-in-the-u-s/24496/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Reports Higher Revenues</title>
		<link>http://www.stockbloghub.com/2009/11/14/gsk-glaxosmithkline-reports-higher-revenues/20425</link>
		<comments>http://www.stockbloghub.com/2009/11/14/gsk-glaxosmithkline-reports-higher-revenues/20425#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:58:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20425</guid>
		<description><![CDATA[GlaxoSmithKline, plc (GSK) reported third quarter income of 92 cents per American Depository Share (ADS), 3 cents below the Zacks Consensus Estimate. The company reported earnings of 94 cents in the year-ago period. Third quarter 2009 revenue increased 3%, with growth being driven by strong performances in emerging markets (up 25%), Japan (up 19%) and Consumer Healthcare (up 8%). We were pleased to see growth in Consumer Healthcare revenue despite the global slowdown. Meanwhile, US sales continued to be impacted by generic competition with revenue declining 12%. Sales of products like Imigran (down 74%), Lamictal (down 21%) and Requip (down 30%) and Wellbutrin XL (down 81%) kept declining. Pharmaceutical product revenue increased 2% with sales being driven by Advair/Seretide (up 5%) and Relenza. Relenza benefited from continued orders from several ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/gsk-glaxosmithkline-reports-higher-revenues/20425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Top Performer for Thurs: Par Pharmaceutical Companies</title>
		<link>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743</link>
		<comments>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743#comments</comments>
		<pubDate>Thu, 15 Oct 2009 22:29:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17743</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session. In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days. The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000. Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today&#8217;s Zacks #1 Rank List: Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Plc Expands Presence in China With Jiangsu Walvax Biotech Joint Venture</title>
		<link>http://www.stockbloghub.com/2009/10/12/gsk-glaxosmithkline-plc-expands-presence-in-china-with-jiangsu-walvax-biotech-joint-venture/17394</link>
		<comments>http://www.stockbloghub.com/2009/10/12/gsk-glaxosmithkline-plc-expands-presence-in-china-with-jiangsu-walvax-biotech-joint-venture/17394#comments</comments>
		<pubDate>Mon, 12 Oct 2009 16:51:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17394</guid>
		<description><![CDATA[GlaxoSmithKline Plc (GSK) continues to expand its presence in China and other emerging markets. Earlier this week, the company formed a joint venture (JV) with Chinese company, Jiangsu Walvax Biotech Company, for the development and production of pediatric vaccines for measles, mumps and rubella (MMR) for the Chinese market. The joint venture will initially produce Priorix, Glaxo’s vaccine for MMR. Glaxo will also transfer the technology so that the JV will be able to manufacture the vaccines locally over time. The JV will also build a new manufacturing facility for Priorix, which will be supplied to China’s public vaccine market once the facility is operational. Glaxo will be investing a total of £27.4 million in the JV. The company will initially invest £20.1 million and the balance amount of £7.3 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/gsk-glaxosmithkline-plc-expands-presence-in-china-with-jiangsu-walvax-biotech-joint-venture/17394/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Pharma Majors to Gain from India</title>
		<link>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677</link>
		<comments>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12677</guid>
		<description><![CDATA[All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Settles Lawsuits &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445</link>
		<comments>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445#comments</comments>
		<pubDate>Thu, 13 Aug 2009 00:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Caraco Pharmaceutical Laborato]]></category>
		<category><![CDATA[CPD]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[GeoPharma Inc.]]></category>
		<category><![CDATA[GORX]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12445</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals &#38; Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents. Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022. Schering has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Lab Ltd. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234</link>
		<comments>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234#comments</comments>
		<pubDate>Wed, 01 Jul 2009 23:22:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=9234</guid>
		<description><![CDATA[Dr. Reddy&#8217;s Lab Ltd. (RDY) doubled its sales from last year in its most recently reported quarter, sending its share price higher by more than 100% in just the last 3 months. Company Description Dr. Reddy&#8217;s, together with its subsidiaries, specializes in developing pharmaceutical and medical technology. The company focuses on drug discovery, generics and care products and has a market cap of $2.8 billion. Fourth-Quarter Results Dr. Reddy&#8217;s reported fourth-quarter results on May 18 that were very solid but impaired by one-time charges. Sales were up big, climbing 50% from last year to $407 million. When stripping out one-time items related to a German subsidiary, earnings came in at 48 cents per share, 15 cents ahead of the consensus. Generics Drive Growth The company noted that its sales growth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/01/dr-reddys-lab-ltd-momentum-zacks-rank-buy/9234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

